RESCINDED: FDA yanks Amarin ANCHOR SPA; shares tumble

Shares of Amarin fell 16% in after-hours trading on 29 October after it revealed the US FDA has rescinded the special protocol assessment (SPA) agreement for the company's placebo-controlled Phase III ANCHOR study of Vascepa (icosapent ethyl) – making it even more unlikely the firm will win an expanded indication for the fish oil pill.